Forsteo ® (teriparatid)

För fullständig produktresumé för Forsteo® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Forsteo® (teriparatid): Farmakodynamisk respons

Användning av teriparatid hos patienter med COVID-19 har inte studerats.

PINP as a Marker for Measuring Pharmacodynamic Response to Teriparatide

For monitoring pharmacodynamic response to teriparatide, PINP may be a useful marker. 

Serum N-terminal propeptide of type I procollagen

  • increases rapidly after initiation

  • remains elevated during continued treatment

  • is not greatly impacted by food or circadian rhythm effects, and

  • has a high signal-to-noise ratio.1-5

Although previous treatment with antiresorptive drugs have been shown to delay the initial PINP response to teriparatide, an increase can be seen with continued teriparatide treatment.5,6

Additionally, increases in PINP have been correlated with later increases in BMD in PMW with osteoporosis treated with teriparatide, but have not been directly validated to predict fracture risk reduction.6

References

1. Chen P, Satterwhite JH, Licata AA, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res. 2005;20(6):962-970. http://dx.doi.org/10.1359/JBMR.050105

2. Eastell R, Krege JH, Chen P, et al. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin. 2006;22(1):61-66. http://dx.doi.org/10.1185/030079905X75096

3. Glover SJ, Eastell R, McCloskey EV, et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone. 2009;45(6):1053-1058. http://dx.doi.org/10.1016/j.bone.2009.07.091

4. Lane NE, See K, Warner M, Krege JH. Algorithm for using a bone formation marker PINP to monitor the response to teriparatide (TPTD) in patients with glucocorticoid-induced osteoporosis (GIO) [abstract]. Arthritis Rheum. 2010;62(suppl S10):957. https://acrabstracts.org/wp-content/uploads/2018/06/2010_ACR_ARHP_Abstract_Supplement.pdf

5. Blumsohn A, Marin F, Nickelsen T, et al. Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide. Osteoporos Int. 2011;22(6):1935-1946. http://dx.doi.org/10.1007/s00198-010-1379-y

6. Krege JH, Lane NE, Harris JM, Miller PD. PINP as a biological response marker during teriparatide treatment for osteoporosis. Osteoporos Int. 2014;25(9):2159-2171. http://dx.doi.org/10.1007/s00198-014-2646-0

Glossary

BMD = bone mineral density

PINP = serum N-terminal propeptide of type I procollagen

PMW = postmenopausal women

Datum fӧr senaste ӧversyn 2020 M01 29


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss